Intuitive Investments Group plc
("IIG" or the "Company")
Portfolio company BioQ Pharma receives CE mark
EU approval for BioQ's next generation medication dispenser
Intuitive Investments Group plc (AIM: IIG), a closed-end investment company focussed on the life sciences sector, announces that its portfolio company, BioQ Pharma Incorporated ("BioQ"), has received CE mark approval for its single-use medication dispenser, the OneDose ReadyfusOR Gen2.
The OneDose ReadyfusOR Gen2 is the second generation of BioQ's original OneDose ReadyfusOR infusion system and was developed to further improve patient convenience. The new system is smaller and lighter than the original product. For the full announcement, visit: https://bioqpharma.com/news/article_20210127
BioQ is a well-established, commercial-stage, medical device and pharmaceutical company, addressing the infusible drugs market. BioQ's proprietary InveniousTM platform comprises a "connect-and-go" drug-device system combination, which can be utilised to improve the delivery of infusible medicines. The key benefits of the platform include reduced cost and complexity compared to current infusion techniques. Further information on BioQ can be found at the company's website: www.bioqpharma.com .
On 21 January 2021, IIG announced its investment of US$1 million by way of unsecured convertible loan notes in BioQ, the Company's second investment from its pipeline of opportunities following its successful IPO in December 2020.
For further information, please contact:
Intuitive Investments Group plc |
|
David Evans |
Via Walbrook PR |
|
|
Strand Hanson Limited - Nominated Adviser |
+44 (0)20 7409 3494 |
James Harris / James Dance / James Bellman |
|
|
|
Turner Pope Investments (TPI) Ltd - Broker |
+44 (0)20 3657 0050 |
Ben Turner / James Pope / Andrew Thacker |
|
|
|
Walbrook PR Limited - Media & Investor Relations |
+44 (0)20 7933 8780 or intuitive@walbrookpr.com |
Paul McManus |
+44 (0) 7980 541 893 |
About Intuitive Investments Group plc
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.